Therapeutic Efficacy of Combined Extracorporeal Shock Wave Therapy and Platelet-Rich Plasma Therapy in a Rat Model of Acute Achilles Tendinopathy Authors: Fumihide Terakawa, Michiaki Mukai, Nobuyasu Ochiai, Eiko Hashimoto, Fumiya Hattori, Nanako Yamakawa, Ryohei Sawada, Yutoku Yamada, Ikuko Tajiri, Seiji Ohtori Published: 2026 ABSTRACT AbstractBackground:Extracorporeal shock wave therapy (ESWT) and platelet-rich plasma (PRP) therapy are effective treatments for tendinopathy; however, in some cases, these monotherapies are ineffective, leading to a delayed return to competition for athletes or the need for surgical intervention in middle-aged and older patients, creating challenges in clinical practice.Purpose/Hypothesis:Few clinical reports have examined the synergistic therapeutic effects of combined ESWT and PRP therapy in fields other than tendinopathy, such as pseudarthrosis. The authors hypothesized that the combined use of ESWT and PRP would exert a synergistic therapeutic effect on tendon disorders. Consequently, when compared with monotherapy, the effects would be observed earlier, promoting pain relief and tendon healing. This study aimed to evaluate the therapeutic efficacy of combined ESWT and PRP therapy in a rat model of acute Achilles tendinopathy.Study Design:Controlled laboratory study.Methods:Fifty male Sprague-Dawley rats (10 weeks old) were randomly assigned to control, sham, ESWT, PRP, and combined treatment (E+P) groups. Collagenase-induced Achilles tendinopathy was established only in the left hindlimb of all mice, except those in the control group, on day −7. The ESWT, PRP, and E+P groups were administered ESWT on day 0 or injected with PRP on day 1 (stored at −30°C before injection). The load ratios between the injured and healthy hindlimbs were measured on days 0, 7, 14, 21, and 28. Pathologic evaluation and Achilles tendon scoring were performed on day 28.Results:On day 0, the load ratios of the injured limbs were significantly decreased in all groups, except the control group. On day 7, the ESWT and PRP groups demonstrated significant improvements in the ratios as compared with the sham group. The E+P group showed significantly superior improvement when compared with both groups. Pathologic analysis revealed remarkable tendon healing in the E+P group, which significantly outperformed ESWT and PRP monotherapy.Conclusion:ESWT combined with PRP administration produces a synergistic effect, resulting in earlier pain relief and better tendon repair than monotherapy alone.Clinical Relevance:The combined use of ESWT and PRP may offer an enhanced therapeutic strategy for tendinopathies in clinical settings.Keywords: tendinopathy, extracorporeal shock wave therapy, platelet-rich plasma, combination therapy Tendinopathy is a common condition among athletes and the elderly.12,22 Its current treatment options include pharmacotherapy with oral or topical medications, use of orthotic devices (eg, tennis elbow bands), physical therapy, local steroid injections, extracorporeal shock wave therapy (ESWT), and platelet-rich plasma (PRP) therapy.14,36 Among these, ESWT and PRP therapy have garnered significant attention in recent years as treatments that provide symptomatic relief and demonstrate tissue-regenerative effects.8,20,39,43,46 According to previous literature, although monotherapy comprising ESWT or PRP for tendinopathy has specific effects or moderate therapeutic efficacy in athletes and middle-aged or older patients, it is insufficient.4,7,28,43 Additionally, refractory tendinopathy sometimes necessitates surgical intervention. 18 One critical issue is that the therapeutic effects of monotherapy comprising ESWT or PRP are often reported 1.5 to 3 months after treatment; therefore, they may not support early return to sports for athletes or early improvement in workplace performance among middle-aged and older individuals.9,27,32,43 To address these issues, we combined ESWT and PRP therapy. Although the evidence level is low, the combined therapy reportedly exerts synergistic effects in the treatment of nonunion, knee osteoarthritis, and partial rotator cuff tears.3,21,24 Furthermore, in a case report, this combined therapy led to a cure after 6 weeks in the case of a stress fracture of the proximal phalanx of the great toe that had not healed after 3 months of nonoperative treatment. 35 The only previous report on the use of this combined therapy for tendon disorders pertains to partial rotator cuff tears. 21 As basic research regarding this is lacking, its mechanisms remain unclear. To our knowledge, no studies have focused on the timing of the onset of its therapeutic effects. Therefore, we hypothesized that the combined use of ESWT and PRP might accelerate the onset and enhance the therapeutic effects of the treatment in tendon disorders. Thus, this study aimed to evaluate the therapeutic efficacy of combined ESWT and PRP therapy in a rat model of acute Achilles tendinopathy. Methods Study Design Fifty-three male Sprague-Dawley rats (Japan SLC) weighing 300 to 350 g were used in this study. The rats were housed in a controlled environment with a 12-hour light/dark cycle and maintained at a temperature range of 21°C to 23°C and a humidity level of 45% to 65%. All rats were provided ad libitum access to water and food and fed a standard rodent diet (CRF-1; Oriental Yeast). All animal procedures were approved by the University Institutional Animal Care and Use Committee (2-418 and 3-341). Three rats were sacrificed to obtain PRP, and the remaining 50 rats were randomly divided into the following 5 groups of 10 rats each: control, sham treatment, only ESWT, only PRP therapy, and combined therapy comprising ESWT and PRP (E+P) (Figure 1). Computer-generated random sequences (RAND function in Microsoft Excel) were used for randomization. Baseline information of the 5 groups is provided in Supplemental Table 1. No significant differences in weight among the 5 groups were observed. An a priori power analysis was performed in G*Power 3.1 (Heinrich-Heine-Universität) to determine the sample size. Because no similar experiments have been conducted, we calculated an effect size of f = 0.53 based on pilot data (n = 3 per group). To achieve α = .05 and power = 0.80, the required sample size was 50 (n = 10 per group). Experimental scheme. The subjects were divided into 5 groups: control, sham, extracorporeal shock wave therapy (ESWT), platelet-rich plasma (PRP), and ESWT+PRP. The model was created by injecting phosphate-buffered saline (PBS) or collagenase into the left hindlimb on day −7. The relevant groups were administered ESWT on day 0 and/or injected with normal saline (NS) or PRP on day 1. A static weightbearing test was conducted on days −7, 0, 7, 14, 21, and 28, and the Achilles tendon of the affected limb was harvested on day 28. All injections and application of ESWT were performed under general anesthesia by injecting a mixture of medetomidine (0.9 mg/kg), midazolam (2.4 mg/kg), and butorphanol (0.3 mg/kg). Postoperatively, the rats were allowed to engage in unrestricted cage movements in a clean environment and were supplied with clean water and feed. Collagenase was injected into the left hindlimb to induce tendinopathy in the sham, ESWT, PRP, and E+P groups. The right hindlimbs were not injured or treated. After anesthesia, a 3- to 5-mm skin incision was made just lateral to the Achilles tendon of the left hindlimb, and the subcutaneous tissue was dissected to expose the Achilles tendon. In total, 0.6 mg of bacterial collagenase I (total 40 µL, 0.015 mg/µL in phosphate-buffered saline [PBS]; Sigma-Aldrich) was injected under direct visualization with a 30-gauge needle. In the control group, an equivalent volume of PBS was administered to the left hindlimb of the rats after the same procedure (Figure 1). This dose of collagenase was compared with the dose reported previously (0.3 mg, 20 µL)41,42 and its double (0.6 mg, 40 µL), and the latter (0.6 mg, 40 µL) was adopted for this experiment because it induced more stable pain (Supplemental Figure 1). Therapy Protocols in Each Group The study protocol for each group is shown in Figure 1. The day of PBS or collagenase injection into the affected limb was day −7, and the day of treatment initiation was defined as day 0. On day −7, PBS was injected into the affected limb of the control group, whereas collagenase was injected into the sham, ESWT, PRP, and E+P groups. On day 0, all rats underwent a static weightbearing (SWB) test. After the test, ESWT was administered to the ESWT and E+P groups under general anesthesia. On day 1, PRP was injected into the injured limbs of the PRP and E+P groups. ESWT Procedure ESWT was applied just above the Achilles tendon of the left hindlimb of the rats in the ESWT and E+P groups under general anesthesia. ESWT was delivered by a radial pressure wave and performed with a Swiss Dolor Clast device (Electro Medical Systems). The impulse was 1000; the frequency, 4 Hz; the pressure of the ESWT, 1 bar; and the energy flux density, 0.02 mJ/mm2 per pulse. ESWT was applied by a radial handpiece with a 15-mm applicator and coupling gel. The applicator was positioned directly over the midportion of the Achilles tendon. To standardize the conditions, general anesthesia was administered to the control, sham, and PRP groups, which did not undergo ESWT application. The ESWT handpiece was pressed against the affected limb to provide physical stimulation without shock waves, and handling and duration times were matched. This irradiation condition was determined by conducting a pilot study using the same radial ESWT irradiation conditions reported in our previous study involving an inflammatory pain model, in which complete Freund adjuvant was subcutaneously injected in the plantar surface of the right hindpaw of rats. 13 Observation of the treatment effect in this research model was confirmed (data not shown). This method was implemented because few reports of the use of radial ESWT in animal tendon experiments exist. PRP Preparation and Injection Technique PRP was prepared from blood obtained from 3 donor rats; therefore, it was an allogenic preparation. Preparation was performed following a previously described protocol.30,38 Immediately after the rats were sacrificed, 8 mL of blood was extracted from the hearts via an 18-gauge needle and mixed with 0.1M sodium citrate (0.8 mL) in a centrifuge tube. The blood was centrifuged at 250g for 10 minutes and then at 1000g for 15 minutes. The supernatant, which contained PRP and the buffy coat, was collected in 1-mL aliquots, transferred to microcentrifuge tubes (Eppendorf), and centrifuged again at 700g for 5 minutes. The supernatant, which contained concentrated platelets and is referred to as PRP, was subsequently collected in 800-μL aliquots. The platelet concentration of the PRP was confirmed by submitting the samples to Fujifilm VET Systems Co, Ltd, for analysis. PRP was not exogenously activated; instead, it was immediately frozen and stored at −30°C until use (Figure 2). Specifically, PRP underwent only a single freeze-thaw cycle. Platelet-rich plasma (PRP) preparation protocol. Blood was centrifuged at 250g for 10 minutes and at 1000g for 15 minutes. The supernatant, which contained PRP and the buffy coat, was collected in 1-mL aliquots, transferred to microcentrifuge tubes (Eppendorf), and centrifuged again at 700g for 5 minutes. The supernatant, except for small red blood cells, was referred to as PRP. On day 1, 40 µL of PRP was injected into the affected Achilles tendon approximately 10 mm from the calcaneal insertion under direct visualization using a 30-gauge needle in the PRP and E+P groups under anesthesia. To standardize the conditions, general anesthesia was administered to the control, sham, and ESWT groups, and an equivalent volume of normal saline was injected into the affected limb instead of PRP (Figure 1). SWB Test Weight distribution in the right and left hindlimbs was measured by a capacitance meter (IITC Life Science), as previously reported. 42 The rats were placed in the testing box and adapted to the apparatus for approximately 5 minutes before measurement. Before day 0, the rats were placed in the correct position within the box once as a habituation procedure for weight measurement. The right hindlimb was positioned on the right force plate in the box and the left hindlimb on the left. The weight (grams) distributed in each hindlimb was measured over 5 seconds. Measurements were taken twice and the mean value calculated. Data are reported as the weight of the left hindlimb as a percentage of the total weight borne by both limbs, as previously reported 42 : (left hindlimb weight / total weight of both hindlimbs) × 100%. This test was performed on days −7, 0, 7, 14, 21, and 28. The rats were randomly allocated by a third party, and the investigator was blinded to group assignments. Histopathology and Evaluation On day 28 after the SWB test, all rats were euthanized with carbon dioxide gas, and the Achilles tendons of the left hindlimbs were harvested immediately. The tendon was harvested by detaching it from the calcaneal insertion to the myotendinous junction. The specimen had a length of approximately 15 mm. The Achilles tendons were immersed in 4% paraformaldehyde for preservation, followed by fixation and paraffin embedding. Sections of 5-μm thickness were prepared from each group for hematoxylin-eosin (H&E) staining (n = 5). H&E-stained 5-µm sections were analyzed with a microscope (BZ-X810; KEYENCE) under a 40× objective. The scoring system adopted in this study was considered practical owing to its simplicity, as it required evaluation based only on H&E staining.5,29 Six parameters—fiber structure, fiber arrangement, nuclei rounding, inflammation, increased vascularity, and cell density—were quantified by a 0-3 grading scale: 0 (normal), 1 (slightly abnormal), 2 (moderately abnormal), and 3 (maximally abnormal) (Supplemental Table 2). In this grading system, a perfectly normal tendon was scored 0, and a maximally abnormal tendon was scored 18. Three sections were randomly selected from each sample and blindly evaluated by 3 independent assessors. The mean score was used for comparison. Statistical Analyses All statistical analyses were performed in Prism 9 (GraphPad Software). A repeated measures analysis of variance of the quantitative results of the SWB test and a 1-way analysis of variance of the semiquantitative results of the histopathologic evaluation were used for multiple-group comparisons, followed by Tukey multiple-comparison tests. Experimental data are expressed as mean and standard deviation. Significance levels were set at P < .05, P < .01, and P < .001. Results PRP Preparation Regarding the blood cell components and platelet concentration rate of the PRP, the components of the PRP preparations are shown in Table 1 and Figure 3. Table 1Blood Cell Counts of Whole Blood and PRP With Platelet Dose Administered to Achilles Tendon a WBC, Cells/µLHemoglobin, g/dLPlatelets, 104/µLTotal Injected Platelets, 106/RatWhole blood4100 ± 134512.3 ± 0.494.1 ± 7.337.6 ± 2.9PRP833 ± 6350.1 ± 0.1259.2 ± 57.2Concentration ratio2.7 ± 0.4aThe table shows the measured values for each blood cell type, the number of platelets administered per rat Achilles tendon, and the platelet concentration rate. Data are shown as mean ± SD (n = 3 per group). PRP, platelet-rich plasma; WBC, white blood cells. Blood Cell Counts of Whole Blood and PRP With Platelet Dose Administered to Achilles Tendon a The table shows the measured values for each blood cell type, the number of platelets administered per rat Achilles tendon, and the platelet concentration rate. Data are shown as mean ± SD (n = 3 per group). PRP, platelet-rich plasma; WBC, white blood cells. Blood cell counts of whole blood and platelet-rich plasma (PRP). The data from Table 1 are shown in a graph. The number of white and red blood cells in the PRP was lower than that in whole blood. The platelet count in PRP was higher than that in whole blood, and the average concentration rate was 2.7 times higher. Data are shown as mean ± SD (n = 3 per group). Hb, hemoglobin; PLT, platelets; WBC, white blood cells. The mean platelet concentration in the PRP preparations was approximately 2.7-fold higher than that in whole blood. However, the mean leukocyte and hemoglobin concentrations in PRP were clearly lower than those in whole blood, at <1/10th the levels. Clinical PRP typically falls within 2.5 to 5 times the baseline value, so this preparation falls within the low to moderate range.16,40 SWB Test At day −7, there was no significant difference in the left hindlimb–bearing ratio among the 5 groups. On day 0, the left hindlimb–bearing ratios in the sham, ESWT, PRP, and E+P groups were significantly lower than those in the control group. The affected hindlimb–bearing ratio in the control group was approximately 0.5 thereafter. On day 7, the left hindlimb–bearing ratios in the ESWT and PRP groups significantly improved when compared with those in the sham group. The affected limb–bearing ratio of the E+P group improved further, reaching a level comparable to that of the control group without a significant difference. At days 14, 21, and 28, the left hindlimb–bearing ratios in the ESWT, PRP, and E+P groups were significantly improved over those in the sham group and were not significantly different from those in the control group (Figure 4). The between-group statistical analysis results at major time points are shown in Table 2. All data of each group at each time point and between-group statistical analysis results are shown in Supplemental Tables 3 and 4. Percentage of weightbearing on the affected limb in the static weightbearing (SWB) test. The weightbearing ratio of the affected limb is expressed as a percentage, with a lower percentage indicating greater pain in the affected limb. Data are shown as mean ± SD (n = 10 per group at each time point). †Significant differences with respect to the control group. ††P < .01. †††P < .001. *Significant differences with respect to the treatment groups. *P < .05. **P < .01. ***P < .001. ESWT, extracorporeal shock wave therapy; PRP, platelet-rich plasma. Table 2Between-Group Statistical Analysis Results at Major Time Points During the Static Weightbearing Test a Day: GroupsAdjusted P ValueMean Difference95% CI0 Control vs sham.00230.1610.06124 to 0.2608 Control vs ESWT<.00010.1540.1026 to 0.2054 Control vs PRP<.00010.1470.09831 to 0.1957 Control vs ESWT+PRP<.00010.1450.07944 to 0.2106 Sham vs ESWT.9995−0.007−0.1100 to 0.09598 Sham vs PRP.9918−0.014−0.1163 to 0.08830 Sham vs ESWT+PRP.9901−0.016−0.1237 to 0.09170 ESWT vs PRP.9962−0.007−0.06653 to 0.05253 ESWT vs ESWT+PRP.9952−0.009−0.08143 to 0.06343 PRP vs ESWT+PRP>.9999−0.002−0.07306 to 0.069067 Control vs sham<.00010.1250.08479 to 0.1652 Control vs ESWT.00010.070.03460 to 0.1054 Control vs PRP.00030.0680.02993 to 0.1061 Control vs ESWT+PRP.81290.017−0.03124 to 0.06524 Sham vs ESWT.0035−0.055−0.09356 to −0.01644 Sham vs PRP.0042−0.057−0.09787 to −0.01613 Sham vs ESWT+PRP<.0001−0.108−0.1581 to −0.05790 ESWT vs PRP.9998−0.002−0.03823 to 0.03423 ESWT vs ESWT+PRP.0241−0.053−0.1001 to −0.005912 PRP vs ESWT+PRP.0379−0.051−0.09971 to −0.00228514 Control vs sham.00620.1080.02910 to 0.1869 Control vs ESWT>.99990.002−0.04662 to 0.05062 Control vs PRP.92290.011−0.03043 to 0.05243 Control vs ESWT+PRP.9974−0.005−0.05169 to 0.04169 Sham vs ESWT.0074−0.106−0.1854 to −0.02662 Sham vs PRP.0125−0.097−0.1739 to −0.02012 Sham vs ESWT+PRP.0043−0.113−0.1916 to −0.03436 ESWT vs PRP.96550.009−0.03400 to 0.05200 ESWT vs ESWT+PRP.9914−0.007−0.05496 to 0.04096 PRP vs ESWT+PRP.7481−0.016−0.05653 to 0.02453aP values, mean differences, and 95% CIs for the affected-limb load ratio at days 0, 7, and 14 are presented. ESWT, extracorporeal shock wave therapy; PRP, platelet-rich plasma. Between-Group Statistical Analysis Results at Major Time Points During the Static Weightbearing Test a P values, mean differences, and 95% CIs for the affected-limb load ratio at days 0, 7, and 14 are presented. ESWT, extracorporeal shock wave therapy; PRP, platelet-rich plasma. Histopathology To evaluate the effect of single or combined treatment with ESWT and PRP on collagenase-induced Achilles tendon injury in rats, a semiquantitative analysis of 6 histologic parameters of Achilles tendon quality on day 28 was performed by 3 blinded evaluators. First, we present each group's representative H&E-stained images and qualitative findings. In the control group, continuous long fibrous tendon tissue was observed in a parallel and closely packed arrangement with no destruction of the fiber structure or abnormal alignment. There was minimal infiltration of inflammatory cells and little evidence of neovascularization (Figure 5, A and B). Images of left Achilles tendon tissue with hematoxylin and eosin staining. Control group: (A) low and (B) high magnification. Sham group: (C) low and (D) high magnification. ESWT group: (E) low and (F) high magnification. PRP group: (G) low and (H) high magnification. ESWT+PRP group: (I) low and (J) high magnification. Arrows indicate areas with red blood cell clustering, signifying neovascularization. Triangles indicate regions with high cell density. ESWT, extracorporeal shock wave therapy; PRP, platelet-rich plasma. In the sham group, the tendon fibers appeared thin and short, lacked continuity, and had an irregular arrangement. Nuclei of varying sizes and shapes were densely distributed, with many exhibiting a rounded morphology. Inflammatory cell infiltration and angiogenesis were observed in approximately 30% of the total area (Figure 5, C and D). In the ESWT group, tendon fibers were thin, irregularly distributed, and partially interwoven. Nuclei of varying sizes and shapes, including many with rounded morphology, were densely present. Additionally, inflammatory cell infiltration and angiogenesis were noted in approximately 20% of the total area (Figure 5, E and F). In the PRP group, the tendon fibers were broader and densely arranged, although they remained short and irregularly aligned. The nuclei exhibited a rounded morphology; however, the overall cell density was not particularly high. Capillary proliferation and inflammatory cell infiltration were observed (Figure 5, G and H). In the E+P group, there was some structural disruption of the fiber arrangement, but it was significantly milder than that in the sham, ESWT, and PRP groups and similar to that in the control group. Additionally, nuclear rounding, inflammatory cell infiltration, and capillary proliferation were observed, although these findings were milder than those in the other 3 groups (Figure 5, I and J). Significant improvements were noted in the total score of the ESWT and PRP groups as compared with the sham group. Although there was no significant difference between the ESWT and PRP groups, the score of the E+P group was significantly higher than that of either group (Figure 6A). The total scores of each group and statistical data among groups are shown in Tables 3 and 4. The scores of each item and the statistical data used for between-group comparisons are shown in Supplemental Tables 5 and 6. Pathologic evaluation of tendon healing. Analysis of Achilles tendon section histology on day 28 in each group. Data are shown as mean ± SD (n = 5 per group). (A) Total score of all 6 histologic parameters. (B-G) Scores of fiber structures, fiber arrangement, nuclear rounding, inflammatory area, increased vascularity, and cell density. †Significant differences with respect to the control group. †P < .05. ††P < .01. †††P < .001. *Significant differences with respect to the treatment groups. *P < .05. **P < .01. ***P < .001. ESWT, extracorporeal shock wave therapy; PRP, platelet-rich plasma. Table 3Total Histopathologic Scores of Each Group a ControlShamESWTPRPESWT+PRPTotal score0.4 ± 0.5516.6 ± 0.5513.6 ± 1.5211.6 ± 1.348.5 ± 1.05aData are shown as mean ± SD (n = 5 per group). ESWT, extracorporeal shock wave therapy; PRP, platelet-rich plasma. Total Histopathologic Scores of Each Group a Data are shown as mean ± SD (n = 5 per group). ESWT, extracorporeal shock wave therapy; PRP, platelet-rich plasma. Table 4Between-Group Statistical Analysis Results and Total Histopathologic Scores a Total ScoreGroupsAdjusted P ValueMean Difference95% CIControl vs sham<.0001−16.2−18.27 to −14.13Control vs ESWT<.0001−13.2−15.27 to −11.13Control vs PRP<.0001−11.2−13.27 to −9.127Control vs ESWT+PRP<.0001−8.2−10.27 to −6.127Sham vs ESWT.002730.9268 to 5.073Sham vs PRP<.000152.927 to 7.073Sham vs ESWT+PRP<.000185.927 to 10.07ESWT vs PRP.06192−0.07318 to 4.073ESWT vs ESWT+PRP<.000152.927 to 7.073PRP vs ESWT+PRP.002730.9268 to 5.073aP values, mean differences, and 95% CIs for the total histopathologic scores are presented. ESWT, extracorporeal shock wave therapy; PRP, platelet-rich plasma. Between-Group Statistical Analysis Results and Total Histopathologic Scores a P values, mean differences, and 95% CIs for the total histopathologic scores are presented. ESWT, extracorporeal shock wave therapy; PRP, platelet-rich plasma. When individual parameters were compared, significant improvements in the fiber structure score were noted in the ESWT and PRP groups versus the sham group, with the E+P group showing greater improvement than both groups (Figure 6B). Regarding fiber arrangement, significant improvements occurred in the PRP and E+P groups as compared with the sham group. The E+P group showed significant improvement over the ESWT group, but there was no significant difference between the E+P and PRP groups (Figure 6C). There was no significant improvement in nuclear rounding in the ESWT or PRP group when compared with the sham group, yet a significant improvement was noted in the E+P group (Figure 6D). There was also no significant improvement in the inflammatory area across all groups (Figure 6E). Regarding increased vascularity, the ESWT and PRP groups did not show significant improvements when compared with the sham group, but the E+P group demonstrated significant improvements (Figure 6F). No significant improvement in cell density was observed in the ESWT group versus the sham group; however, significant improvements were noted in the PRP and E+P groups, with the E+P group showing a significant difference from the ESWT group (Figure 6G). Discussion In this study, we used PRP that was 2.7-fold concentrated, leukocyte poor, allogeneic, nonactivated, and stored at −30°C and underwent a single freeze-thaw cycle. Most PRP preparation kits used in clinical practice are leukocyte poor, with a concentration ratio of approximately 2.5 to 5 times.16,40 Therefore, leukocyte-poor PRP was adopted. Although the concentration was somewhat low, it was within the acceptable range. Next, it is important to note the clinical significance of the allogeneic cryopreserved PRP used in this study, which differs from the autologous fresh PRP derived from peripheral blood, most commonly used in clinical practice. Several studies have reported that significant growth factors in PRP are largely preserved through freeze-thaw cycles; additionally, even when some growth factors exhibited slight decreases, no differences in the proliferation of human fibroblasts, chondrocytes, and synovial cells were observed.2,25,37 Furthermore, animal experiments that compared fresh PRP and cryopreserved PRP in a rat Achilles tendon transection model showed no significant differences. 19 Moreover, from a technical standpoint, the use of allogenic cryopreserved PRP enables sufficient blood collection from rats and reduces variability in the administered PRP. Therefore, it is widely used in animal experiments.1,30,38 However, immune mechanisms may be involved with allogeneic PRP, thus leading to unnecessary inflammation, which is a limitation. In our study using a rat model of acute Achilles tendinopathy, the ESWT and PRP groups in the SWB test showed significant improvement in the affected limb–bearing ratio when compared with the sham group on day 7. There were no significant differences between the ESWT and PRP groups. Notably, the E+P group demonstrated significantly greater pain improvement on day 7 than the ESWT and PRP groups, with no significant difference when compared with the control group. Additionally, we excised the Achilles tendons of the affected limbs 28 days after treatment and performed H&E staining. Regarding the total score, the ESWT and PRP groups showed significant improvements as compared with the sham group, but there was no significant difference between the groups. Notably, the E+P group demonstrated significantly greater improvement than the ESWT and PRP groups, indicating the efficacy of the combined therapy. In terms of specific parameters, the synergistic effect of both treatments was observed in items related to fiber structure. To our knowledge, this study is the first to demonstrate early efficacy and better outcomes for combination therapy using ESWT and PRP therapy in an animal model. The results highlight the potential of this approach as a treatment option for acute tendinopathy in athletes aiming to return to competition early. Moreover, it could improve outcomes in treating chronic tendinopathy in middle-aged and older individuals. Although studies are yet to clarify the underlying mechanism of the synergistic effect of ESWT and PRP therapy in tendon disorders, we consider the following 2 hypotheses. First, we hypothesized that combination therapy may complement the analgesic and tissue regeneration mechanisms associated with each monotherapy. The unique analgesic mechanism of ESWT comprises the degeneration and reinnervation of free nerve endings distributed within the skin. Our previous study reported that epidermal nerve fiber degeneration occurs in ESWT-treated skin, with reinnervation starting approximately 2 weeks after the treatment. 34 Furthermore, Ochiai et al 33 demonstrated that ESWT for rats with knee osteoarthritis reduced dorsal root ganglion neurons that were calcitonin gene-related peptide positive and led to early pain relief. Additionally, a previous study showed that ESWT reduced inflammation by COX-2 degradation in the microenvironment by inhibiting the TLR4-NFκB pathway (Toll-like receptor 4–nuclear factor kappa B), which is a mechanism that has not been identified with PRP, in vivo and in vitro. 15 Although PRP therapy reportedly suppressed proinflammatory cytokines such as tumor necrosis factor α and interleukin 6 secretion, it increased the anti-inflammatory cytokine interleukin 10. Through these anti-inflammatory effects, PRPs contribute to pain relief. 44 Collectively, we hypothesized that shock wave–induced free nerve ending destruction and the anti-inflammatory effects of PRP might act in a complementary manner, contributing to the earlier pain relief noted in the combination therapy. Moreover, ESWT and PRP have been reported to increase angiogenesis and growth factor expression in tendon disorders. ESWT reportedly increases vascular endothelial growth factor (VEGF) expression and induces endothelial nitric oxide synthase production, thereby promoting angiogenesis. Beyond VEGF, ESWT induces the expression of other growth factors, such as transforming growth factor β and insulin-like growth factor 1, promoting collagen precursor production.8,39 Similarly, PRP contains growth factors and cytokines such as platelet-derived growth factor, transforming growth factor β, and VEGF, promoting tissue repair and angiogenesis by enhancing cell proliferation, migration, and differentiation. 10 Although these effects on angiogenesis and growth factor expression are broadly similar, we speculated that combination therapy may exert a synergistic effect, as ESWT induces intracellular responses to shock wave while PRP supplies platelet-derived exogenous growth factors. Second, we hypothesized that ESWT irradiation may enhance the responsiveness of irradiated cells to tissue-regenerative factors such as PRP-derived growth factors. Regarding ESWT in our previous study, Murata et al 31 reported that radial shock waves significantly enhanced reporter gene transfection in rabbit chondrocytes. Furthermore, in the field of urology, basic studies revealed improvements in the delivery efficacy of anticancer drugs after ESWT application in the cancer area.6,11,26 Regarding PRP, although various growth factors in PRP reportedly play an important role, 45 recent reports suggest that PRP may exert its effects by transferring mitochondria contained in it into cells within the target tissues.17,23 Collectively, the results of these previous studies suggest that ESWT may promote the reactivity or intracellular transfer of several factors contained in PRP, leading to a synergistic effect. Further research on these 2 hypothesized mechanisms of combination therapy comprising ESWT and PRP is necessary. This study has some limitations. First, the rat model that we used was an acute model, potentially differing from the chronic tendinopathy commonly seen in clinical settings. Second, the PRP used in this study was allogenic and prefrozen. Some properties of frozen PRP differ from those of fresh PRP derived from autologous blood, which is widely used clinically, and may induce some immune response. Third, although ESWT was administered only once, the clinical protocol typically involves multiple sessions. Future studies should verify the optimal irradiation protocol for combination therapy including PRP. Furthermore, it is necessary to investigate the optimal ESWT irradiation conditions for combination therapy. Fourth, the functional assessment was limited to the SWB test; however, additional tests (eg, footprint or gait analysis) may have provided more comprehensive results. Fifth, we used only H&E staining, which may lack sensitivity for detecting changes in the matrix composition; therefore, it would have been preferable to use other stains such as Masson trichrome or safranin O. Sixth, this study examined the combined use of ESWT and PRP over a relatively short observation period of up to 28 days after treatment; therefore, the long-term persistence of therapeutic effects could not be evaluated. Finally, the mechanisms underlying the synergistic effects of the combined therapy remain unclear, as quantitative polymerase chain reaction and protein identification analyses were not performed. Further research is necessary to address these limitations. Conclusion ESWT combined with PRP therapy produces a significant synergistic effect, leading to more effective pain relief and enhanced tendon tissue healing than either treatment alone. Patients receiving this combination therapy may experience earlier pain relief and superior structural repair outcomes, highlighting its potential as an advanced therapeutic strategy for tendon injuries. Supplemental Material sj-docx-1-ojs-10.1177_23259671261438101 – Supplemental material for Therapeutic Efficacy of Combined Extracorporeal Shock Wave Therapy and Platelet-Rich Plasma Therapy in a Rat Model of Acute Achilles Tendinopathy Supplemental material, sj-docx-1-ojs-10.1177_23259671261438101 for Therapeutic Efficacy of Combined Extracorporeal Shock Wave Therapy and Platelet-Rich Plasma Therapy in a Rat Model of Acute Achilles Tendinopathy by Fumihide Terakawa, Michiaki Mukai, Nobuyasu Ochiai, Eiko Hashimoto, Fumiya Hattori, Nanako Yamakawa, Ryohei Sawada, Yutoku Yamada, Ikuko Tajiri and Seiji Ohtori in Orthopaedic Journal of Sports Medicine Footnotes Final revision submitted December 28, 2025; accepted March 1, 2026. The authors declared that they have no conflicts of interest in the authorship and publication of this contribution. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto. Ethical approval for this study was obtained from the University Institutional Animal Care and Use Committee of Chiba University (2-418 and 3-341). ORCID iDs: Fumihide Terakawa https://orcid.org/0000-0001-5861-6033 Michiaki Mukai https://orcid.org/0000-0002-4673-4734 Yutoku Yamada https://orcid.org/0009-0002-3570-764X Supplemental Material: Supplemental Material for this article is available at https://journals.sagepub.com/doi/full/10.1177/23259671261438101# supplementary-materials. References Associated Data Supplementary Materials sj-docx-1-ojs-10.1177_23259671261438101 – Supplemental material for Therapeutic Efficacy of Combined Extracorporeal Shock Wave Therapy and Platelet-Rich Plasma Therapy in a Rat Model of Acute Achilles Tendinopathy Supplemental material, sj-docx-1-ojs-10.1177_23259671261438101 for Therapeutic Efficacy of Combined Extracorporeal Shock Wave Therapy and Platelet-Rich Plasma Therapy in a Rat Model of Acute Achilles Tendinopathy by Fumihide Terakawa, Michiaki Mukai, Nobuyasu Ochiai, Eiko Hashimoto, Fumiya Hattori, Nanako Yamakawa, Ryohei Sawada, Yutoku Yamada, Ikuko Tajiri and Seiji Ohtori in Orthopaedic Journal of Sports Medicine